Key points are not available for this paper at this time.
In the Semaglutide Treatment Effect in People with obesity and HFpEF (STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms, physical limitations, and exercise function, and reduced bodyweight in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Whether semaglutide improves functional status, as assessed by NYHA functional class, is unknown.
Published in JACC, this study provides strong evidence that strength training, particularly when combined with aerobic exercise, is associated with a lower risk of major cardiovascular disease in women, a topic of growing interest in preventive cardiology.
Schou et al. (Mon,) studied this question.